Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and Sound Pharmaceuticals completed this new Phase 2a study testing SPI-1005, an investigational drug that contains ebselen, as a new treatment for bipolar disorder.

Trees in the shape of two heads, one with green leaves in blue sky and the other with empty branches in grey sky.

Professor Phil Cowen, Department of Psychiatry, University of Oxford, said,

“This work was done in collaboration with colleagues from the Department of Pharmacology at the University of Oxford who discovered that a drug called ebselen had pharmacological properties similar to those of the mood-stabilising drug, lithium. Lithium is a very useful agent in bipolar disorder but is not well-tolerated and requires regular blood tests. Ebselen would be free from these problems.

"The study shows important preliminary evidence of therapeutic activity for SPI-1005 in bipolar disorder. This pilot investigation has given us critical information to inform design of future trials and has confirmed the safety of SPI-1005 in a group of patients with severe mental illness taking multiple medications.” 

The study was funded by the Stanley Medical Research Institute and the medication was supplied by Sound Pharmaceuticals.

To read the full press release

To read the full study, A phase 2a randomised, double-blind, plcebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

No Evidence of Significant Increase in Risk of Suicide in First Months of Pandemic

COVID-19 Mental Health Suicide

A new observational study is the first to examine suicides occurring during the early phase of the COVID-19 pandemic in multiple countries and finds that suicide numbers largely remained unchanged or declined in the pandemic’s early months, however continued monitoring is needed.

Largest study to date suggests link between COVID-19 infection and subsequent mental health and neurological conditions

COVID-19 Mental Health

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates.

Opportunities for Final Goodbyes Must be Prioritised in COVID-19 Pandemic

COVID-19 Child and Adolescent Psychiatry Mental Health

Bereaved relatives described the ongoing pain of being absent at the end of a loved-one's life. Many had not seen their relative for weeks or months due to the pandemic. Opportunities must be prioritised for essential connections between families at end-of-life care.

Seven in Ten Patients Hospitalised with COVID-19 Not Fully Recovered After Five Months

COVID-19 Mental Health

The majority of survivors who left hospital following COVID-19 did not fully recover five months after discharge and continued to experience negative impacts on their physical and mental health, as well as ability to work, according to results released by the PHOSP-COVID study.

Healthy Start, Happy Start Study

Child and Adolescent Psychiatry Early intervention Mental Health

Healthy Start, Happy start is a randomised controlled trial that tested the clinical- and cost-effectiveness of a brief parenting programme - Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline (VIPP-SD).

Oxford Awarded Major Funding to Probe Childhood Poverty and Social Inequalities

Awards Child and adolescent Mental Health

Ground-breaking multi-disciplinary research is to be launched today by the University of Oxford into the impact of poverty and social inequalities in early childhood, thanks to major funding from the Leverhulme Trust.